 |
Common Tradename
 |
ZARONTIN |
|
|
Class
|
anticonvulsant |
|
|
Dosage, Adult (usual)
|
initial
500mg daily (QD-BID), maintenance 20-30mg/kg daily (QD-BID),
MAX 1.5g/day |
|
|
Dosage, Pediatric, (usual)
|
initial:
3-6years: 250mg/day QD; over 6 years:500 mg/day QD |
|
maint:
20-30mg/kg/day |
|
|
Dose Adjustments:
|
severe
renal impairment |
|
|
How Supplied
|
250
MG CAPSULE |
|
250
MG/5 ML SOLUTION |
|
250
MG/5 ML SYRUP |
|
|
Indications
|
absence
seizures |
|
|
Contraindications
|
hypersensitivity
to succinimides |
|
|
Adverse Effects
|
blood
dyscrasias |
|
ataxia |
|
headache |
|
N/V |
|
drowsiness |
|
|
Drug Interactions
|
carbamazepine |
|
evening
primrose oil |
|
fosphenytoin |
|
ginkgo |
|
phenobarbital |
|
phenytoin |
|
|
Pregnancy Category
|
C |
|
|
Breast Feeding
|
controversial |
|
|
Notes
|
sudden
withdrawal may precipitate seizures |
|
